Johnson & Johnson says long-term data boosts Icotyde for plaque psoriasis

Johnson & Johnson's icotrokinra (Icotyde) outperformed placebo and was noninferior to ustekinumab in a phase 3 trial for moderate to severe plaque psoriasis. At week 16, 55.2% of patients on icotrokinra achieved PASI 90 vs. 3.6% on placebo. At week 28, icotrokinra was noninferior to ustekinumab, with numerically higher response rates but no statistical superiority. The drug is already approved in the US, Europe, Japan, and China.

The FDA approved a labeling update for J&J's LAZCLUZE (lazertinib) on 11/12/2026. The change, under supplement SUPPL-5, affects the package insert only, with no alteration to the drug's indication or efficacy. LAZCLUZE was originally approved on 08/19/2024. The drug is available in 80MG and 240MG tablet strengths. According to the filing, this is an administrative update for an already approved drug.

The NCCN updated its guidelines to include GSK's belantamab mafodotin (Blenrep) plus bortezomib and dexamethasone as a category 1 recommendation for lenalidomide-refractory multiple myeloma. The update also includes two other belantamab triplets under 'Useful in Certain Circumstances' for patients with 3 or more prior therapies. The changes follow the drug's FDA approval in October 2025 and reflect its efficacy in clinical trials.

A California jury awarded $34.21M to a man who claimed J&J's talcum powder caused his mesothelioma. The jury found J&J 40% liable for not warning about asbestos contamination, but no punitive damages were awarded. Dr. Scholl’s settled before trial.

Johnson & Johnson's icotrokinra (Icotyde) showed improvement in psoriatic arthritis (PsA) symptoms at 16 weeks in a phase 3 trial, with 200-mg and 400-mg doses outperforming placebo. The drug, approved for psoriasis, is being studied for PsA, with no new safety signals identified. Experts highlight its potential as an oral treatment option. The trial compared icotrokinra to ustekinumab, with results showing efficacy and safety. Final 52-week data are pending.

Johnson & Johnson's Icotyde pill showed improvement in psoriatic arthritis symptoms in a Phase 3 trial, with 58% of patients on the drug achieving at least 20% improvement compared to 41% on placebo. The drug is not yet approved for this use, and full safety data are pending. The company plans further trials, with results expected in 2027.